Open AccessNexavar (Sorafenib) Granted FDA Priority Review for RAI-refractory Differentiated Thyroid Cancer
Publication year - 2013
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000435401.50699.58
Subject(s) - sorafenib , thyroid cancer , refractory (planetary science) , medicine , cancer , oncology , cancer research , hepatocellular carcinoma , biology , astrobiology